Literature DB >> 9000573

The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.

I F Pollack1, R L Hamilton, S D Finkelstein, J W Campbell, A J Martinez, R N Sherwin, M E Bozik, S M Gollin.   

Abstract

The prognosis for children with high-grade gliomas remains somewhat unpredictable. Although prolonged disease control is sometimes achieved after surgery, radiotherapy, and chemotherapy, most patients exhibit rapid disease progression. Because p53-dependent apoptosis mechanisms are involved in the cytotoxic effects of irradiation and chemotherapy, we questioned whether p53 status might be associated with outcome in childhood malignant gliomas. Therefore, we examined p53 status, both immunohistochemically and by direct sequencing of exons 5-8, in a series of 29 archival pediatric malignant non-brainstem gliomas treated consecutively at our institution between 1975 and 1992. Eighteen tumors had dense p53 staining in the majority of cells, although only 11 had mutations of the p53 gene (TP53). On univariate analysis, there was a significant association between p53 overexpression and a shorter progression-free survival (PFS) and overall survival (OS; P = 0.019 and 0.013, respectively; rank sum test). In addition, there was a significant association between TP53 mutations and a poorer PFS (P = 0.04), and a strong trend toward a shorter OS among patients with TP53 mutations (P = 0.06). Median PFS and OS for patients with TP53-mutated tumors were 6 months and 16 months, respectively, and for those with p53 overexpression 5.5 months and 14 months, respectively, versus 16 months and 25 months, respectively, for those without TP53 mutations and 25 months and >4 years, respectively, for those without p53 overexpression. The percentage of patients in this series with TP53 mutations (37.9%) was substantially higher than in previous studies of childhood gliomas and comparable to the frequency of mutations noted in adult gliomas. However, both TP53 mutation and p53 overexpression were significantly less frequent in tumors from children younger than 4 than from older children (P = 0.02 and 0.01, respectively). These results indicate that p53 mutation and expression status may be associated with prognosis in childhood malignant gliomas, and thus may provide a basis for stratifying patients biologically in future malignant glioma studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9000573

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  11q13 allelic imbalance discriminates pulmonary carcinoids from tumorlets. A microdissection-based genotyping approach useful in clinical practice.

Authors:  S D Finkelstein; T Hasegawa; T Colby; S A Yousem
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  Cold-temperature plastic resin embedding of liver for DNA- and RNA-based genotyping.

Authors:  S D Finkelstein; R Dhir; M Rabinovitz; M Bischeglia; P A Swalsky; P DeFlavia; J Woods; A Bakker; M Becich
Journal:  J Mol Diagn       Date:  1999-11       Impact factor: 5.568

3.  Primary Central Nervous System Tumors in Children.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

Review 4.  Paediatric and adult malignant glioma: close relatives or distant cousins?

Authors:  Chris Jones; Lara Perryman; Darren Hargrave
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

5.  Alterations of p53, BCL-2, and hMSH2 protein expression in the normal brain tissues, gliosis, and gliomas.

Authors:  Mahmoud R Hussein; Rabab M H El-Ghorori; Yasser G Abd El-Rahman
Journal:  Int J Exp Pathol       Date:  2006-08       Impact factor: 1.925

Review 6.  Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies.

Authors:  Mandeep S Tamber; Krishan Bansal; Muh-Lii Liang; Todd G Mainprize; Bodour Salhia; Paul Northcott; Michael Taylor; James T Rutka
Journal:  Childs Nerv Syst       Date:  2006-09-02       Impact factor: 1.475

7.  Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas.

Authors:  Craig Horbinski; Ronald L Hamilton; Yuri Nikiforov; Ian F Pollack
Journal:  Acta Neuropathol       Date:  2010-01-01       Impact factor: 17.088

Review 8.  Molecular analysis of pediatric brain tumors.

Authors:  Jaclyn A Biegel; Ian F Pollack
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

Review 9.  Identifying novel therapeutic agents using xenograft models of pediatric cancer.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

10.  Significance of p53 and CD31 in astrogliomas.

Authors:  Abdul-Zaher M Khattab; Magdy I Ahmed; Mohamed A Fouad; Waleed A Essa
Journal:  Med Oncol       Date:  2008-09-20       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.